Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation
| Autor: | Bikash Medhi, Alka Bhatia, Rupa Joshi, Sree Lalitha Bojja, Ranjana W. Minz, Shashi Anand |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.medical_specialty business.industry Immunology Inflammation Status epilepticus Epileptogenesis Neuroprotection Proinflammatory cytokine Metformin 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Endocrinology Internal medicine medicine Pharmacology (medical) medicine.symptom business 030217 neurology & neurosurgery PI3K/AKT/mTOR pathway Neuroinflammation medicine.drug |
| Zdroj: | Inflammopharmacology. 29:137-151 |
| ISSN: | 1568-5608 0925-4692 |
| Popis: | The initial precipitating injury such as SE progresses to chronic epilepsy through multiple epileptogenic processes. Early epileptogenic events are generally characterized by neuroinflammation, neurodegeneration and abnormal neurogenesis in the hippocampus. Metformin has exhibited anti-inflammatory and neuroprotective properties in numerous studies. The current study attempts to investigate the effect of metformin on seizure-induced inflammation and neuronal degeneration, and the involvement of the mTOR pathway. Status epilepticus (SE) was induced in male Wistar rats with systemic administration of Lithium (127 mg/kg) and Pilocarpine (30 mg/kg). In test rats, Metformin 100 mg/kg or 200 mg/kg was administered orally for 7 days, followed by SE induction. Results indicate that metformin did not alter the SE profile significantly which was evident by the behavioural scoring and electroencephalogram (EEG) recordings. However, metformin 200 mg/kg attenuated the SE-induced glial activation (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink